Our tumor cell panel included key clinical markers (ER, HER2, and Ki67), markers of growth-associated signaling pathways (p-mTOR, pRb, and pS6), markers relevant for immune interactions (HLA-ABC and PD-L1), and key lineage markers (CK5, CK14, and GATA3). Here, ERBB2 is linked to neoplasm.